Nathalie Vigneron
Overview
Explore the profile of Nathalie Vigneron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borges F, Laureano R, Vanmeerbeek I, Sprooten J, Demeulenaere O, Govaerts J, et al.
Oncoimmunology
. 2024 Oct;
13(1):2412876.
PMID: 39398476
Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing...
2.
McAuliffe J, Panetti S, Steffke E, Wicki A, Pereira-Almeida V, Noblecourt L, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39384196
Background: Melanoma antigen gene (MAGE)-type antigens are promising targets for cancer immunotherapy as they are expressed in cancer cells but not in normal tissues, except for male germline cells. The...
3.
Ferrari V, Stroobant V, Abi Habib J, Naulaerts S, Van den Eynde B, Vigneron N
J Immunol
. 2022 Jun;
208(12):2817-2828.
PMID: 35688464
By tying peptide fragments originally distant in parental proteins, the proteasome can generate spliced peptides that are recognized by CTL. This occurs by transpeptidation involving a peptide-acyl-enzyme intermediate and another...
4.
Abi Habib J, Lesenfants J, Vigneron N, Van den Eynde B
Cells
. 2022 Feb;
11(3).
PMID: 35159231
Four proteasome subtypes are commonly present in mammalian tissues: standard proteasomes, which contain the standard catalytic subunits β1, β2 and β5; immunoproteasomes containing the immuno-subunits β1i, β2i and β5i; and...
5.
Lahman M, Schmitt T, Paulson K, Vigneron N, Buenrostro D, Wagener F, et al.
Sci Transl Med
. 2022 Feb;
14(631):eabg8070.
PMID: 35138909
Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient,...
6.
Lichti C, Vigneron N, Clauser K, Van den Eynde B, Bassani-Sternberg M
Cancer Immunol Res
. 2022 Feb;
10(3):275-284.
PMID: 35105607
Within the tumor immunology community, the topic of proteasomal spliced peptides (PSP) has generated a great deal of controversy. In the earliest reports, careful biological validation led to the conclusion...
7.
Klaessens S, Stroobant V, Hoffmann D, Gyrd-Hansen M, Pilotte L, Vigneron N, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(23).
PMID: 34074763
Maintaining stable tryptophan levels is required to control neuronal and immune activity. We report that tryptophan homeostasis is largely controlled by the stability of tryptophan 2,3-dioxygenase (TDO), the hepatic enzyme...
8.
Abi Habib J, De Plaen E, Stroobant V, Zivkovic D, Bousquet M, Guillaume B, et al.
Sci Rep
. 2020 Sep;
10(1):15765.
PMID: 32978409
The proteasome is responsible for selective degradation of proteins. It exists in mammalian cells under four main subtypes, which differ by the combination of their catalytic subunits: the standard proteasome...
9.
Vigneron N, Stroobant V, Ma W, Michaux A, Van den Eynde B
Methods Mol Biol
. 2019 Jun;
1988:159-186.
PMID: 31147940
Identification of antigenic peptides recognized by cytolytic T lymphocytes (CTL) is a prerequisite for the development of targeted cancer immunotherapy approaches. This chapter provides a global approach for the identification...
10.
Zanker D, Oveissi S, Tscharke D, Duan M, Wan S, Zhang X, et al.
J Immunol
. 2019 May;
202(12):3370-3380.
PMID: 31092636
The importance of antiviral CD8 T cell recognition of alternative reading frame (ARF)-derived peptides is uncertain. In this study, we describe an epitope (NS1-ARF2) present in a predicted 14-residue peptide...